Lilly, Novo Dip as Proposed Medicare Coverage for GLP-1 Pilot Thrown Off Balance

Why It Matters

The postponement stalls a key policy lever aimed at making high‑cost weight‑loss medicines more affordable, directly affecting the earnings outlook of the sector’s leading manufacturers and the pace of patient access.

Key Takeaways

• CMS postpones BALANCE pilot, delaying Medicare GLP‑1 coverage
• Lilly shares fell ~2%, Novo down 4% after delay
• Revenue hit up to $500M for Lilly; $3.3B if PBMs opt out
• CVS declines participation; UnitedHealth raises concerns but hasn't refused
• Bridge program extended to Dec 2027, providing interim GLP‑1 access

Pulse Analysis

The CMS BALANCE initiative was designed to negotiate directly with drug makers to lower the cost of GLP‑1 therapies, which have become a cornerstone in obesity treatment. By bundling payments and leveraging Medicare’s bargaining power, the model promised broader patient access while curbing the rapid price escalation seen in recent launches. The delay, however, underscores the complexities of aligning federal policy with the commercial strategies of insurers and manufacturers, especially as the obesity market expands beyond traditional diabetes indications.

Investors reacted sharply to the news, with Eli Lilly and Novo Nordisk seeing their stocks tumble. Analysts at Truist warned that the immediate impact could shave up to $500 million from Lilly’s peak Medicare Part D sales of Zepbound/Foundayo, a figure that could balloon to $3.3 billion if every PBM opts out of the program. Novo’s newer Wegovy pill, already reaching thousands of patients, may see slower uptake without the anticipated Medicare boost, though the company’s broader pipeline could cushion the hit. Companies are also eyeing alternative distribution channels, such as direct‑to‑patient telehealth platforms, to offset potential shortfalls.

The broader industry implication is a heightened focus on the role of PBMs and large insurers in shaping drug accessibility. CVS’s outright refusal and UnitedHealth’s cautious stance signal that even the biggest payers are wary of the program’s structure and reimbursement mechanics. As the Bridge program now runs through the end of 2027, manufacturers must balance short‑term sales tactics with long‑term pricing negotiations, while policymakers may need to refine the model to win broader stakeholder buy‑in. The outcome will influence not only obesity drug pricing but also future Medicare innovation pilots.